SCHEMBL481078

SCHEMBL481078

N#Cc1ccnc(CO)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.43
MBOAT4 Q96T53 1/20 0.40
CLK4 Q9HAZ1 1/20 0.39
KCNH2 Q12809 1/20 0.36
NPY5R Q15761 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
VNN1 O95497 1/20 0.35
RECQL P46063 1/20 0.34
EGLN2 Q96KS0 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
ENPP2 Q13822 1/20 0.33
GRM4 Q14833 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29478779 1.00 NOTUM (0.43) NOTUMMBOAT4CLK4KCNH2NPY5R
SCHEMBL3870198 0.85 CCNC (0.40) NOTUMMBOAT4CLK4KCNH2NPY5R
SCHEMBL14546705 0.80 MBOAT4 (0.40) MBOAT4CLK4KCNH2NPY5RKDM4C
SCHEMBL18078827 0.80 MBOAT4 (0.40) MBOAT4CLK4KDM4CCCNCCDK8
SCHEMBL3242600 0.80 CYP1A2 (0.44) MBOAT4CLK4KCNH2NPY5RCCNC
SCHEMBL30607265 0.80 MBOAT4 (0.40) MBOAT4CLK4KDM4CCCNCCDK8
SCHEMBL19640161 0.80 HDAC8 (0.41) RECQL
SCHEMBL16532586 0.80 MBOAT4 (0.43) MBOAT4CLK4KDM4CCCNCCDK8
SCHEMBL7666624 0.80 MBOAT4 (0.40) MBOAT4CLK4KCNH2NPY5RKDM4C
SCHEMBL17168474 0.80 MBOAT4 (0.40) MBOAT4CLK4KCNH2NPY5RKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 WO disclosed
CN-112390755-B Heteroaryl method for amine 中国科学院理化技术研究所 2024-08-02 CN disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 WO disclosed
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2022-08-18 US disclosed
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2022-08-18 US disclosed
EP-0533131-A1 Process for selectively mono-ortho-hydroxy alkylation of 4-substituted pyridine derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1993-03-24 EP disclosed
EP-0509769-A2 Heterocyclic amides having HLE inhibiting activity ZENECA LIMITED (GB) 1992-10-21 EP disclosed
US-4607107-A CHEMICAL INTERMEDIATES FOR HESTAMINE H2-ANTAGONISTS SMITH KLINE & FRENCH LABORATORIES LTD. (GB) 1986-08-19 US disclosed
EP-0049173-B1 PYRIMIDONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL DERIVATIVES CONTAINING THEM SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1985-07-03 EP disclosed
EP-0039989-B1 PYRIMIDONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1984-08-29 EP disclosed
US-4439609-A 4-TERT-AMINOALKYL, 2-AMINOALKOXY OR 2-AMINOALKYLENETHIOALKYL SUBSTITUTED, CHEMICAL INTERMEDIATES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1984-03-27 US disclosed
US-4388317-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1983-06-14 US disclosed
US-4385058-A HISTAMINE H2-ANTAGONISTS SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1983-05-24 US disclosed
EP-0049173-A2 Pyrimidone derivatives, processes for their preparation and pharmaceutical derivatives containing them SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1982-04-07 EP disclosed
EP-0039989-A1 Pyrimidone derivatives, processes for their preparation and pharmaceutical compositions containing them SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1981-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB NOTUM 3972/4885MBOAT4 2568/4885CLK4 1852/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB NOTUM 3972/4885MBOAT4 2568/4885CLK4 1852/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB NOTUM 3972/4885MBOAT4 2568/4885CLK4 1852/4885
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 NOTUM 3848/4885MBOAT4 1963/4885CLK4 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.